Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

NCT05589480 | Completed

• 1 other identifier: Zhejiang CH
• Study Type: observational
• Target: 226
• Locations: 1 country
• Sites: 1

Brief Summary

Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value. A retrospective analysis of patients with PCa who underwent radical resection at Zhejiang Cancer Hospital (Hangzhou, China) from January 2013 to December 2020. The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical PCa surgery in the investigators' hospital. The investigators used the PyRadiomics platform to extract image features.

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

• Recurrence-free survival

  1 year

Study Arms (2)

postoperative recurrence

Other: preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

postoperative non-recurrence

Other: preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

Interventions

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features. OTHER

preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.

postoperative non-recurrence; postoperative recurrence

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with PCa who underwent radical resection

You may qualify if:

• Have the results of enhanced CT examination of the pancreas within 1 month before surgery in our hospital;
• Radical resection of pancreatic cancer was performed in our hospital;
• There are follow-up results in our hospital, and the follow-up endpoints include disease recurrence or at least 12 months.
• Complete clinical medical records and imaging data.

You may not qualify if:

• non-R0 resection;
• Combined with other malignant tumors
• The patient's imaging data has technical problems or the lesion is too small (less than 1cm), which is not suitable for omics analysis.

Sponsors & Collaborators

• Luo Cong: lead

Study Sites (1)

Zhejiang Province Cancer Hospital

Hangzhou, Zhejiang, 310000, China

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Deputy Director

Study Record Dates

• First Submitted: October 18, 2022
• First Posted: October 21, 2022
• Study Start: August 1, 2022
• Primary Completion: August 20, 2022
• Study Completion: September 1, 2022
• Last Updated: December 11, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)